ORIC provides rinzimetostat Phase 1b dose optimization update

Oric Pharmaceuticals, Inc.

Update covers dose optimization data from Phase 1b trial of rinzimetostat (ORIC-944).
No numerical results or conclusions are disclosed in the 8-K filing itself.
Full data is included in the attached presentation (Exhibit 99.1) dated March 31, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.